PureTech Health (NASDAQ:PRTC) Sees Unusually-High Trading Volume

PureTech Health plc (NASDAQ:PRTC) shares saw an uptick in trading volume on Thursday . 8,968 shares traded hands during trading, an increase of 140% from the previous session’s volume of 3,730 shares.The stock last traded at $20.98 and had previously closed at $20.04.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PRTC. Leerink Partnrs raised PureTech Health to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners initiated coverage on PureTech Health in a research note on Monday, September 9th. They issued an “outperform” rating and a $45.00 target price for the company.

PureTech Health Price Performance

The company has a 50 day moving average price of $21.59 and a 200 day moving average price of $25.27.

Institutional Investors Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new position in shares of PureTech Health plc (NASDAQ:PRTC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health as of its most recent SEC filing. Institutional investors own 0.04% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.